Oslo, January 9, 2025: Ultimovacs ASA held its extraordinary general meeting today January 9, 2025. All the matters on the agenda were approved.
The minutes from the meeting are enclosed and available at the company’s website.
For further information, please see www.ultimovacs.com or contact:
Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASA
Email: je@radforsk.no
Phone: +47 480 96 355
Hans Vassgård Eid, CFO and Interim CEO, Ultimovacs ASA
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632
Attachment
Esteemed Life Sciences Leader Joins Board to Enhance Strategic Direction During Company Expansion Ben Daverman,…
New data to be presented from Company’s lead product candidate SENTI-202 for the treatment of…
Academic research teams of selected projects participate in a translational research program that eliminates barriers…
FDA-cleared home sleep test provides an effective and simplified solution to obstructive sleep apnea testing…
$3.1 million of new orders received during the current calendar year$6.6 million customer program backlog…
ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
